Clinical Trial Update: An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Open, exploratory Phase 2 clinical trial evaluating CM336 for treatment of immune thrombocytopenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• CM336 (CM336)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Immune Thrombocytopenia (ITP), Treatment | Phase 2 | Status: RECRUITING